Mykofenolatmofetil Accord (Mycophenolate Mofetil)

Mycophenolate Mofetil blocks the enzyme inosine monophosphate dehydrogenase, which is crucial for making guanosine nucleotides. Lymphocytes depend on this pathway for proliferation, so the drug selectively reduces T‑ and B‑cell expansion, limiting the immune attack on a graft.

The specific dose of Mykofenolatmofetil Accord is determined by the prescribing physician based on the type of transplant, patient weight, renal function, and other clinical factors. Only a qualified healthcare professional should set the dosing regimen.

Safety data for Mycophenolate Mofetil in pregnancy are limited, and the drug may cause fetal harm. Women of childbearing potential should use effective contraception. Breastfeeding is generally not recommended while on this medication unless the benefits outweigh the risks.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with calcineurin inhibitors like tacrolimus, Mycophenolate Mofetil offers a different mechanism—targeting nucleotide synthesis rather than calcineurin signaling. It is often used in combination therapy to provide synergistic immunosuppression while allowing lower doses of each agent, potentially reducing individual drug toxicity.

Mykofenolatmofetil Accord should be stored at room temperature, below 25 °C, in its original packaging to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

The medication is taken orally, usually as tablets or capsules, with or without food as directed by the prescriber. Swallow the dose whole with a full glass of water; do not crush or chew unless specifically instructed.

Serious risks include severe infections, leukopenia, anemia, and an increased long‑term risk of certain malignancies. Patients should be monitored regularly for blood‑cell counts and signs of infection, and any unusual symptoms should be reported promptly to a healthcare provider.

Mykofenolatmofetil Accord is contraindicated in patients with known hypersensitivity to Mycophenolate Mofetil or any component of the formulation. It should also be avoided in individuals receiving live vaccines or those with uncontrolled infections without appropriate medical supervision.